Trial · NCT07125027
A Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE
NCT07125027, Not applicable, Recruiting, National University of Natural Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE. Trials, record NCT07125027. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07125027
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE
- NCT number
- NCT07125027
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 32 participants, estimated
- Lead sponsor
- National University of Natural Medicine
- Conditions
- Lumbosacral Radiculopathy, Sciatica, Chronic Low Back Pain With a Neuropathic Component, Radiculopathy Lumbar, Chronic Pain (Back / Neck)
- Interventions
- Move-MORE
- First posted
- 2025-08-15
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Proportion | End of study | The proportion of patients contacted who consent to screening |
| Primary | Retention | End of study | Retention will be assessed by tracking the percentage of participants who complete their primary endpoint visit |
| Primary | Client Satisfaction Questionnaire | Week 4, Week 8, Week 20 | Intervention Satisfaction. Min = 8, Max = 32. Higher score = greater satisfaction. |
| Primary | Adherence | End of study | The proportion of participants completing at least 5 intervention sessions |
| Primary | Adverse Events | End of study | The frequency and severity of adverse events (AEs) and serious adverse events (SAEs) occurring during the study. |
| Primary | Intervention Satisfaction | Week 4, Week 8 | Satisfaction will be measured using the Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is a self-report measure designed to assess satisfaction with health services. |
| Secondary | Oswestry Disability Index | Week 0, Week 4, Week 8, Week 20 | Activities of daily living. Min = 0%, Max = 100%. Higher score = worse outcomes. |
| Secondary | painDETECT Questionnaire | Week 0, Week 4, Week 8, Week 20 | Neuropathic Pain. Min = -1, Max = 38. Higher score = worse outcomes. |
| Secondary | Visual Analog Scale | Daily | Pain Intensity. Min = 0, Max = 10. Higher score = worse pain |
| Secondary | Complex Medical Symptoms Inventory | Week 0, Week 4, Week 8, Week 20 | A questionnaire to assess pain hypersensitivity and allodynia. The CMSI inquires about participants' pain experiences specifically related to hypersensitivity and allodynia to discern whether an individual may experience central sensitization. Currently, no direct measures of self-reported nociplastic pain exist, thus measures of central sensitization can be used as surrogate measures for this construct. The CSI has previously been shown to have strong test-retest reliability in chronic pain patients. |
1 to 10 of 37Source ClinicalTrials.gov
See all 37 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K12NS130673 | University of Michigan (UM) HEAL Initiative National K12 Clinical Pain Career Development Program (UM-HCPDP) | WILLIAMS, DAVID A; CLAUW, DANIEL J; HARTE, STEVEN EDWARD | UNIVERSITY OF MICHIGAN AT ANN ARBOR | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Other outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07125027
GET https://conductscience.org/api/trials/v1/NCT07125027/registered?page=2